Monday, December 16 2019
  1. Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Scarpitta R, Zanna I, Aretini P, Gambino G, Scatena C, Mei B, Ghilli M, Rossetti E, Roncella M, Congregati C, Bonci F, Naccarato AG, Palli D, Caligo MA. Breast Cancer Res Treat. 2019 Dec;178(3): 557-564.
  2. Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease. Del Grosso A, Galliani M, Angella L, Santi M, Tonazzini I, Parlanti G, Signore G, Cecchini M. Science Advances, Volume 5, Issue 11, 20 November 2019.
  3. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Moosavi F, Giovannetti E, Saso L, Firuzi O. Crit Rev Clin Lab Sci. 2019 Dec;56(8):533-566.
  4. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Br J Cancer. 2019 Oct;121(9):725-737.
  5. Fast-diffusing p75NTR monomers support apoptosis and growth cone collapse by neurotrophin ligands. Marchetti L, Bonsignore F, Gobbo F, Amodeo R, Calvello M, Jacob A, Signore G, Schirripa Spagnolo C, Porciani D, Mainardi M, Beltram F, Luin S, Cattaneo A. Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21563-21572.
  6. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. Cancers (Basel). 2019 Sep 6;11(9).
  7. Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma. Naccarato AG, Lessi F, Zavaglia K, Scatena C, Al Hamad MA, Aretini P, Menicagli M, Roncella M, Ghilli M, Caligo MA, Mazzanti CM, Bevilacqua G. Aging (Albany NY). 2019 Sep 13;11(17):7236-7241.
  8. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E. Drug Resist Updat. 2019 Sep;46:100644.
  9. Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro. Scatena C, Franceschi S, Franzini M, Sanguinetti C, Romiti N, Caponi L, Mandalà M, Mazzanti CM, Naccarato AG. Cancer Cell Int. 2019 Aug 28;19:223. doi: 10.1186/s12935-019-0938-3.
  10. Remarkable Effect of [Li(G4)]TFSI Solvate Ionic Liquid (SIL) on the Regio- and Stereoselective Ring Opening of α-Gluco Carbasugar 1,2-Epoxides. Di Pietro S, Bordoni V, Mezzetta A, Chiappe C, Signore G, Guazzelli L, Di Bussolo V. Molecules. 2019 Aug 14;24(16).
  11. Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. Meijer LL, Puik JR, Le Large TYS, Heger M, Dijk F, Funel N, Wurdinger T, Garajová I, van Grieken NCT, van de Wiel MA, Giovannetti E, Kazemier G. Cancers (Basel). 2019 Aug 15;11(8). pii: E1181.
  12. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma? Liu DSK, Mato Prado M, Giovannetti E, Jiao LR, Krell J, Frampton AE. Expert Rev Mol Diagn. 2019 Jul;19(7):553-558.
  13. Ultra-high resolution MALDI-FTICR-MSI analysis of intact proteins in mouse and human pancreas tissue. Piga I, Heijs B, Nicolardi S, Giusti L , Marselli L, Marchetti P, Mazzoni MR, Lucacchini, A., McDonnell, L.A. International Journal of Mass Spectrometry, Volume 437, March 2019, Pages 10-16.
  14. Quantitative Microproteomics Based Characterization of the Central and Peripheral Nervous System of a Mouse Model of Krabbe Disease. Pellegrini D, Del Grosso A, Angella L, Giordano N, Dilillo M, Tonazzini I, Caleo M, Cecchini M, McDonnell LA. Mol Cell Proteomics. 2019 Jun;18(6):1227-1241.
  15. Poly(Lactide‐Co‐Glycolide) Nanoparticles Co‐Loaded with Chlorophyllin and Quantum Dots as Photodynamic Therapy Agents. Galliani M, Signore G.  ChemPlusChem. Volume84, Issue11 November 2019, Pages 1653-1658.
  16. Whole exome sequencing in familial isolated primary hyperparathyroidism. Cetani F, Pardi E, Aretini P, Saponaro F, Borsari S, Mazoni L, Apicella M, Civita P, La Ferla M, Caligo MA, Lessi F, Mazzanti CM, Torregrossa L, Oppo A, Marcocci C. J Endocrinol Invest. 2019 Sep 5.
  17. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F. Semin Cancer Biol. 2019 Aug 21. pii: S1044-579X(19)30180-4.
  18. ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer. La Ferla M, Lessi F, Aretini P, Pellegrini D, Franceschi S, Tantillo E, Menicagli M, Marchetti I, Scopelliti C, Civita P, De Angelis C, Diodati L, Bertolini I, Roncella M, McDonnell LA, Hochman J, Del Re M, Scatena C, Naccarato AG, Fontana A, Mazzanti CM. Front Oncol. 2019 Jun 26;9:547.
  19. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells. Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E. Anticancer Res. 2019 Jul;39(7):3615-3620.
  20. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ.. Anticancer Res. 2019 Jul;39(7):3609-3614
  21. A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course "Preclinical and Early-phase Clinical Pharmacology. Capula M, Corno C, El Hassouni B, Li Petri G, Aranđelović S; EORTC PAMM Group. Anticancer Res. 2019 Jul;39(7):3413-3418.
  22. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase. Clinical Pharmacology El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group. Anticancer Res. 2019 Jul;39(7):3303-3309.
  23. Laser Capture Microdissection and RNA-Seq Analysis: High Sensitivity Approaches to Explain Histopathological Heterogeneity in Human Glioblastoma FFPE Archived Tissues. Civita P, Franceschi S, Aretini P, Ortenzi V, Menicagli M, Lessi F, Pasqualetti F, Naccarato AG, Mazzanti CM.. Front Oncol. 2019 Jun  7;9:482.
  24. Rescuing cones and daylight vision in retinitis pigmentosa mice. Guadagni V, Biagioni M, Novelli E, Aretini P, Mazzanti CM, Strettoi E. FASEB J. 2019 Jun 14:fj201900414R.
  25. Molecular profiling of microinvasive breast cancer microenvironment progression. Lessi F, Scatena C, Aretini P, Menicagli M, Franceschi S, Naccarato AG, Mazzanti CM. J Transl Med. 2019 Jun 3;17(1):187.
  26. Pharmacogenetics of treatments for pancreatic cancer. El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E.  Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447.
  27. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Biochem Pharmacol. 2019 Aug;166:128-138.
  28. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E. Cancers (Basel). 2019 May 8;11(5). pii: E638.
  29. Nanocarriers for Protein Delivery to the Cytosol: Assessing the Endosomal Escape of Poly(Lactide-co-Glycolide)-Poly(Ethylene Imine) Nanoparticles. Galliani M, Tremolanti C, Signore G. Nanomaterials (Basel). 2019 Apr 23;9(4). pii: E652.
  30. MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response. Barravecchia I, Mariotti S, Pucci A, Scebba F, De Cesari C, Bicciato S, Tagliafico E, Tenedini E, Vindigni C, Cecchini M, Berti G, Vitiello M, Poliseno L, Mazzanti CM, Angeloni D. Biochim Biophys Acta Mol Basis Dis. 2019 Apr 18. pii: S0925-4439(19)30119-X.
  31. Monoallelic expression in melanoma. Silcock L, Almabrazi H, Mokrab Y, Jithesh P, Al-Hashmi M, James N, Mathew R, Mattei V, Bedognetti D, Lessi F, Temanni R, Seliger B, Al-Ali R, Marincola FM, Wang E, Tomei S. J Transl Med. 2019 Apr 5;17(1):112.
  32. Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. Sarogni P, Palumbo O, Servadio A, Astigiano S, D'Alessio B, Gatti V, Cukrov D, Baldari S, Pallotta MM, Aretini P, Dell'Orletta F, Soddu S, Carella M, Toietta G, Barbieri O, Fontanini G, Musio A. J Exp Clin Cancer Res. 2019 Mar 1;38(1):108.
  33. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. Cascioferro S, Parrino B, Petri GL, Cusimano MG, Schillaci D, Di Sarno V, Musella S, Giovannetti E, Cirrincione G, Diana P. Eur J Med Chem. 2019 Apr 1;167:200-210.
  34. Molecular characterization of low grade and high grade bladder cancer. Apollo A, Ortenzi V, Scatena C, Zavaglia K, Aretini P, Lessi F, Franceschi S, Tomei S, Sepich CA, Viacava P, Mazzanti CM, Naccarato AG.. PLoS One. 2019 Jan 16;14(1):e0210635.
  35. Integrative Clustering in Mass Spectrometry Imaging for Enhanced Patient Stratification. Balluff B, Buck A, Martin-Lorenzo M, Dewez F, Langer R, McDonnell LA, Walch A, Heeren RMA. Proteomics Clin Appl. 2019 Jan;13(1):e1800137.
  36. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.  Drug Resist Updat. 2019 Jan;42:1-11.
  37. Ultraviolet Photodissociation of ESI- and MALDI-Generated Protein Ions on a Q-Exactive Mass Spectrometer. Dilillo M, de Graaf EL, Yadav A, Belov ME, McDonnell LA.  J Proteome Res. 2019 Jan 4;18(1):557-564.
  38. Development of a yeast-based system to identify new hBRAFV600E functional interactors. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Poliseno L, Cervelli T. Oncogene. 2019 Feb;38(8):1355-1366.
  39. The inherent molecular stigma in normal breast tissue of BRCA1/2 gene mutation carriers: TC1 and SYNGR2 genes involvement in neoplastic transformation. Mazzanti CM, Franceschi S, Scatena C, Menicagli M, Aretini P, Civita P, Scopelliti C, Tomei S, Tancredi M, Naccarato AG, Caligo MA, Lessi F. The inherent molecular stigma in normal breast tissue of BRCA1/2 gene mutation carriers: TC1 and SYNGR2 genes involvement in neoplastic transformation. January 17, 2019. Journal of Translational Sciences.